Robert Jurgen Van 't Hof

This inventor holds 9 USPTO granted patents, plus 3 CIPO patents and 2 EPO patents. Top assignees: Pimco 2664 Limited, University of Aberdeen. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Jurgen Van 't Hof. Retrieved from https://idiyas.com/inventor/robert-jurgen-van-t-hof

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 88.9

CIPO Patents = 3

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 92(Granted Patents)

Location History:

Aberdeen, GB (2011)
Edinburgh, GB (2009 - 2015)
Lothian, GB (2012 - 2016)

Company Filing History:

University of Aberdeen

patents

Years Active: 2009-2016

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9302984 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use (2016-04-05),

2. 9050329 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use (2015-06-09),

3. 8822507 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use (2014-09-02),

4. 8435968 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use (2013-05-07),

5. 8207167 - Aryl-phenyl-sulfonamide-phenylene compounds and their use (2012-06-26),

6. 7964643 - Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions (2011-06-21),

7. 7598289 - Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions (2009-10-06),

8. 7572825 - Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions (2009-08-11),

9. 7560597 - 2',4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents (2009-07-14),

Title: Robert Jurgen Van 't Hof: Innovator in Therapeutic Compounds

Introduction: Robert Jurgen Van 't Hof, located in Lothian, GB, is a distinguished inventor with a focus on therapeutic compounds. With a total of five patents to his name, his contributions to the medical field are significant. His most recent work revolves around innovative compounds that promise advancements in treatments for various inflammatory and autoimmune disorders.

Latest Patents: One of Robert's latest patents is centered on Aryl-phenyl-sulfonamido-cycloalkyl compounds, collectively referred to as 'APSAC compounds.' This invention delves into their potential use in pharmaceutical compositions designed to treat inflammation, joint destruction, bone loss, and several disorders linked to an overactive immune system. This includes tackling inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, and chronic obstructive pulmonary disease (COPD), among others. Moreover, his research targets conditions associated with bone loss and various forms of cancer, indicating a broad scope of therapeutic applications.

Career Highlights: Throughout his career, Robert Jurgen Van 't Hof has been associated with Pimco 2664 Limited, where his innovative ideas continue to flourish. His role at the company has enabled him to develop groundbreaking therapeutic compounds that contribute to advancements in medical treatment and patient care.

Collaborations: Collaboration plays a vital role in the innovative process, and Robert works alongside talented colleagues such as Iain Robert Greig and Rose Mary Sheridan. Their combined expertise fosters an environment of creativity and productivity, paving the way for remarkable discoveries in therapeutic innovation.

Conclusion: Robert Jurgen Van 't Hof's inventive spirit and dedication to improving health outcomes underscore his importance in the field of therapeutic innovations. With his patents showcasing significant advancements, he continues to contribute positively to the future of medical research and treatment methodologies.

Profile summary based on public USPTO records.